i tng s dng v nhng lu quan trng khi ung Glutathione Vin ung Glutathione c khuyn ngh dnh cho ngi trng thnh t 18 tui tr ln, c bit ph hp vi cc nhm i tng: Ngi c ln da thm nm, tn nhang hoc en sm
Some of the therapeutic strategies so far employed are described in this review
313, 2227 10.1016/j.bbrc.2003.11.081 [DOI] [PubMed] [Google Scholar] 117.Meng G., Ma Y., Xie L., Ferro A
Important discussion points include: Medical history : Disclose any history of thyroid problems (especially MTC), MEN2, pancreatitis, gallbladder disease, kidney disease, gout, liver disease, or alcohol use Treatment goals : Clarify whether niacin therapy is necessary given current lipid management guidelines, which generally favor statins, ezetimibe, PCSK9 inhibitors, or other agents before niacin for cardiovascular risk reduction Glucose monitoring plan : Establish a clear schedule for blood glucose checks and hemoglobin A1c testing (typically every 3 months) to assess the combination's net effect on glycemic control Liver monitoring plan : Discuss the schedule for liver function tests if taking pharmacologic doses of niacin (baseline, 6-8 weeks during titration, and periodically thereafter) Pregnancy planning : If applicable, discuss contraception needs, as tirzepatide may reduce oral contraceptive effectiveness during initiation and dose escalation Symptom management : Review strategies for managing potential side effects from both medications, including the timing of niacin doses to minimize flushing and approaches to mitigate tirzepatide's gastrointestinal effects Patients should specifically ask about the expected timeline for therapeutic effects, warning signs that require immediate medical attention (severe abdominal pain, yellowing of skin/eyes, unusual fatigue, neck swelling), and whether any dose adjustments to existing diabetes medications may be necessary
This supports the idea that GLP-1 RAs as a class are likely friends rather than foes to erectile function, insofar as they ameliorate the underlying causes of ED
Front Psychol 2017, 8, 1531
